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HIV infection is treatable but remains uncurable today, partially due to the virus’s 
integration and latency in the host cell. Latent infection can later cause an active infection in the 
body if the virus resurfaces. Two donors on antiviral therapy for HIV infection are studied, donor 
449 and donor 436. The HIV sequences studied, expressed in the donor’s peripheral blood 
plasma or via an induction of cells via a viral outgrowth assay, contain a deletion or mutation in 
the major splice donor site (MSD) of the 5’ leader sequence (Fig.1). As demonstrated in other 
retroviruses like murine leukemia virus, loss of a primer binding motif in the 5’ leader sequence, 
which also acted as a repressor binding site, lead to an increase in viral expression.1 So, we 
hypothesized that the genetic differences in these sequences may also explain why they were 
detectable even in donors on antiviral therapy. This thesis aims to elucidate possible explanations 
behind sequence differences that lead to differences in infectivity and latency.  
Through construction of eight donor derived dual reporter vectors, in-vitro transfection 
and infection experiments were performed on human cell lines. We have found that our 
constructs are viable to express both mCherry and GFP, and that addition of the HIV trans-
activator Tat increases transcription in our constructs. In addition, a correlation between low 
infection rate and a high degree of latent infection, possibly driven by the size of the deletion, 
has been found in the donor derived sequences. We attempted to activate the long terminal 
repeats (LTRs) during infection using a PMA and ionomycin drug treatment to show that the 
constructs were still functional, yet data was inconclusive due to a loss in cell viability. However, 
because the constructs showed activity during transfection experiments as quantified via 
mCherry reporter expression off of donor LTRs, we can conclude that the leader sequences are 
functional to produce viral particles. We suggest that the differences in infectivity were not due 
to differences in virion protein or HIV RNA production during transfection.  
II. INTRODUCTION 
A. Retroviruses 
Retroviruses are characterized by reverse transcription, via the enzyme reverse 
transcriptase, and integration into the host cell DNA. Integration means that the viral RNA is 
reverse transcribed into DNA and inserted into the host genome, allowing for replication and 
transcription via the host cell machinery. This integration also allows persistent infection as well 
as vertical transmission into offspring, making retroviruses very difficult to cure.4,5 The unique 
properties of retroviruses can also lead to other problems during integration, such as altering 
gene expression, leading to tumor formation.5 Retrovirus integration is a very coordinated step in 
viral proliferation and latency in cells. It has even been shown that upon entry into the nucleus, 
unintegrated viral genomes undergo histone packaging and modifications prior to insertion into 
the host DNA that can affect its expression patterns later.6 Integration of the viral genome is 
performed by the viral integrase enzyme. Integrase regulates the formation of an intasome 
complex that aligns the linear viral DNA (vDNA) with host protein machinery allowing insertion 
into DNA in the host chromosomes.5,7 Use of non-catalytic site integrase inhibitors (NCINIs) or 
integrase strand inhibitors has also been shown to not affect viral processing or reverse 
transcription, yet specifically blocks the integration of the vDNA into the host DNA, thus 
providing more evidence of the specific role of integrase in retroviral integration.5,8 
All retroviruses have three genes known as gag, pol, and env, that encode the necessary 
structural proteins of the virus. Specifically, gag encodes proteins for viral formation, pol 
encodes many important viral enzymes such as the viral protease (Pro), reverse transcriptase 
(RT) and the enzyme needed for integration into the host DNA integrase , and env encodes a 
transmembrane protein needed for entry into host cells.5 Various retroviruses have different 
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splicing and different open reading frames to create other structural proteins; those for HIV will 
be discussed below. 
There are 2 subfamilies of retroviruses orthoretrovirinae and spumaretrovirinae, with 
HIV belonging to the former. Of these two subfamilies, there are 6 genera and 1 genus 
respectively. The main differences between genera is defined by their morphology, assembly, 
open reading frames, transcription, and splicing methods.5 HIV, a lentivirus, assembles at the cell 
membrane and contains conical core morphology; the core encases the RNA and is made of 
capsid protein. Lentiviruses have also been shown to infect cells throughout the cell cycle, during 
both mitosis and non-dividing stages.5,9 Other examples of lentiviruses include SIV, caprine 
arthritis encephalitis virus, and visna virus.5 
B. Human Immunodeficiency virus (HIV) 
The history of HIV first began in 1981 when cases of severe immune deficiency began to 
rise, initially reported as clusters of Kaposi’s sarcoma, a type of cancer, and Pneumocystis 
pneumonia in California and New York city among gay men as described by the Centers of 
Disease Control and Prevention.10 Following its initial characterization, research on acquired 
immunodeficiency syndrome (AIDS), a result of HIV infection, as well as HIV, initially called 
Lymphadenopathy-Associated Virus (LAV) or HTLV-II retrovirus, increased as cases grew 
exponentially.11 
HIV-1 is the most common type of HIV in humans and is studied in this thesis. The 
Human Immunodeficiency virus (HIV) genome is a 9.3 kb long RNA that complexes as a dimer. 
If left untreated, HIV can lead to AIDS. HIV is a positive sense retrovirus, which is characterized 
by reverse transcription of its single stranded linear RNA genome and integration of the provirus 
into the host DNA via the viral enzyme integrase. This integration allows persistent infection that 
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can be reactivated even after lying dormant in the host during treatment.5,14 HIV specifically 
forms a spherical core containing many gaps at the immature phases of assembly, eventually 
forming an ordered core containing nucleocapsid protein that surrounds the RNA dimer. The 
capsid proteins are hexamer or pentamer multimers, and are enveloped by a transmembrane Env 
protein, as well as the host cell’s bilayer during cell budding.13  
 People on antiviral therapy still maintain their reservoir of latent infection, whose cell 
proliferation makes HIV incurable today.5,12 Latent infection of cells is characterized by 
integration of provirus into the host DNA, proliferation through host cell replication machinery, 
and then possible reactivation. A detectable viral load in the body can cause the host’s CD4+ T 
cells to die and could lead to AIDS; Antiretroviral drugs prevent establishment of this detectable 
viral load. Although HIV+ individuals may not contain a detectable viral load on drug therapy, 
targeting the latent reservoirs for eradication is required for a cure to HIV. Resting CD4+ T cells 
are the largest contributors to this latent reservoir population, either through direct infection of 
resting T cells, or infection of activated of CD4+ T cells, who return to a quiescent state after 
infection.15, 16, 17  
In addition, other cell types such as peripheral blood mononuclear cells (PBMCs) and 
hematopoietic stem cells (HSPCs) have been shown to be sources of the latent virus 
reservoir.2,3,15 Actively proliferating HSPC’s that have been infected have been shown to 
produce progeny containing the integrated provirus, and thus could be sources of residual virus if 
the progeny’s latent infection turns active. 14 With treatment, the viral load in the human body 
can remain low, but because not all virus is active, if treatment becomes unavailable, latent virus 
may reactivate and cause serious infection and medical complications in the host. This need for a 
reliable source of treatment highlights the inaccessibility for healthcare treatment for many 
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people due to cost, environment of treatment, stigma, family, gender, or societal pressures and 
further exacerbates the disparity in health between groups.18 
In the study of HIV latency, there are two main approaches to combatting latent virus in 
an effort to find a cure. One hypothetical method attempts to permanently turn off the latent 
virus, meaning the integrated viral genome will not reactivate and hurt the host; antiretroviral 
therapy will therefore not be required to diminish reactivated virus. The second option is to “turn 
on” all the provirus in the cells to become active, so that the virus can be eradicated with current 
or future treatment methods. Current antiretroviral therapy mostly targets either the viral protease 
or reverse transcriptase which prevent virus maturation or viral replication via integration, 
respectively, as well as a combination of treatments.19 Overall, the study of what mechanisms 
allow HIV to be latent in cells, as well as the difference in active vs latent virus between 
different HIV sequences will help increase the understanding of how HIV functions in-vivo.  
BI: 5’ Leader Region of HIV 
HIV contains many different important mechanisms and proteins that drive host cell 
binding, transcription, translation, and assembly. Specifically, this thesis focuses on the role of 
the 5’ leader region in infectivity and latency of 8 HIV constructs. The 5’ region of interest in 
HIV contains the primer binding site, stem loops 1, 2 and 3 (SL1, SL2, SL3), the dimerization 
initiation sequence in stem loop 1 (DIS), and the major splice donor site in stem loop 2 (MSD) 
(Fig 1). The primer binding site is complementary to an initiation tRNA, whose binding initiates 
DNA synthesis from genomic viral RNA (gRNA).5 It has also been shown that binding to the 
primer binding site may also induce dimerization of the gRNA, allowing for RNA packaging.20  
The three stem loops found in this region are important for assembly and packaging of 
the gRNA. Specifically, the Psi sequence of the 5’ leader sequence mediates interaction with the 
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nucleocapsid protein that is required for viral assembly, and is also referred to as stem loop 3.5, 
21,22 Psi interacts with other stem loop regions of the 5’ region in order to mediate other 
important roles in packaging; Stem loop 1 contains the dimer initiation site, made of a 6 
nucleotide palindromic sequence that is important in dimerization of the gRNA prior to 
packaging. DIS has been shown to allow for Watson-Crick base pairing between two full length 
HIV gRNA, allowing for co-packaging of the genome, as well as mixing of HIV sequences if 
more than one exists in the cell.22,23 Stem loop 2, which contains the major splice donor site, has 
been shown to form a platform conformation, whose long-range interaction ability may help 
explain its role in Psi-RNA stabilization, packaging, and splicing.24  
 The major splice donor site is responsible for making many RNA spliced products. 
Transcription initially 
occurs after integration in 
the host cell DNA and is 
performed by the host RNA 
polymerase II. Cleavage of 
proteins is also required for 
HIV to make other proteins 
out of the three precursor 
proteins Gag, Pol, and Env. 
Both Gag and Gag-Pol proteins are made from full length mRNA, while Env is made from 
splicing from the major splice donor site (D1) to various acceptor sites termed A4b, A4c, and 
A5.5,25 The Gag-Pol polyprotein is made due to a -1 frameshift during transcription that occurs at 
about a 5-10% rate due to interaction of the RNA frameshift stimulatory signal and the ribosome, 
Figure 1: Donor 5’ Leader region  
The 8 donor constructs show a deletion or mutation in the major splice donor site. The constructs also 
show deletions in stem loop 1 (SL1), stem loop 2 (SL2), and stem loop 3 (SL3). The construct sequences 
are of interest because their deletion may give insight into why they were detectable in donors on antiviral 
therapy.  
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making the stop codon that separates the two open reading frames no longer in frame.5,26 
Specifically, the MSD is required to create the spliced transcripts for many important proteins 
such as Env, Tat, Rev, and Nef.27 Although the constructs studied contain a deletion in the MSD, 
they may still be infectious, as HIV has been shown to contain alternative MSD sites that may 
facilitate splicing even if the major splice donor site is mutated or missing, as well as 3 other 
donor sites termed D2, D3, and D4.27,28 Specifically, HIV with alternative MSD sites such as 
AC|GG, TA|GT, ATGG|GT that also contain a deleted or defective MSD have been shown to 
still create spliced products needed for essential viral proteins.28  
 The Tat protein is of important interest in this thesis, as it is created via splicing from the 
MSD site, and drives an increase in transcription in HIV-1. At the start of transcription after 
infection, only a small amount of mRNA production occurs and produces Tat, which then drives 
the activation of transcription.29 Tat has also been shown to play a role in cell to cell activation, 
being secreted by infected cells and taken up by uninfected cells leading to gene regulation of 
many immunoregulatory genes.30  
Later protein cleavage of the Gag protein creates the matrix, capsid, and nucleocapsid 
proteins, from Pol the protease, reverse transcriptase, integrase, and dUTPase, and from Env the 
surface and transmembrane proteins.5 Therefore, the major splice donor site, along with the other 
stem loops and primer binding site of the 5’ leader region of HIV play a very important role in 
the function and processing of HIV, yet may have alternative sites if the main site is mutated or 
defective.   
BII: Experimental Background 
 Eight viral donor constructs from 2 donors on antiviral therapy were taken from 
peripheral blood plasma or induced in donor cells via a viral outgrowth assay. These sequences 
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are of interest because their detection at all in donors who had clinically undetectable plasma 
virus level shows a possible explanation for how a MSD site deletion or mutation could lead to 
an increase in expression levels; the MSD site may also contain some sort of repressor binding 
site, and thus when deleted, leads to increased levels of expression. Thus, the study of these 
constructs may also elucidate explanations behind active vs latent mechanisms of HIV. Sequence 
differences and the size of the deletion or mutation could lead to conclusions on how varying 
sites in the 5’ leader sequence can lead to expression or latency. It is also important to note that 
we are unable to quantify how many cells in the donors expressed these specific sequences, yet 
their detection at all is interesting. 
It is unknown information from the donors whether the virus from which our donor 
constructs came from is infectious or not; this can only be determined in-vitro. Thus, we 
investigated the role of these 
various deletions in latency, 
infectivity, and ability of the 
viral constructs, in the 
presence of helper plasmid 
and VSVg, to express our 
reporter, mCherry; mCherry 
expression during transfection 
can be used to measure 
activity of the 5’ leader region. Specifically, it is interesting to note that although all constructs 
studied contain a deletion or mutation in the major splice donor site of stem loop 2, some contain 
deletions in other parts of the 5’ leader sequence such as in stem loop 1 and stem loop 3 that 
 
Figure 2: VT1 Construct mCherry expression demonstrates Gag production by virus 
The VT1 construct contains a deletion in Gag, Pol, Env, and Nef. Gag expression is replaced by the 
reporter mCherry and thus if mCherry is expressed, we can assume that Gag proteins would have 
been expressed in virions that the donor constructs originated from. Tat expression in our constructs 
which only contain the donor LTR not the full-length sequence is determined by the MSD, which in 
these cases is mutated or deleted. We co-transfect with helper containing Tat, Gag, and Pol during 
transfection experiments and VSVg containing Env.  
VT1 
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could also affect their latency, activity, and infectivity (Fig 1). Expression of mCherry, the 
reporter downstream of each specific construct’s leader sequence, demonstrates that the viruses 
would have made Gag, and were packaged in the case of mCherry expression during infection 
(Fig. 2). These sequences were found in virions, meaning that the provirus in the host DNA 
could be transcribed and synthesize the proteins needed for genome packaging. In addition, 
constructs V1 and V2, acquired through a viral outgrowth assay, because they were created by 
induced cells, are at least structurally functional to secrete virions. Therefore, we can assume that 
the constructs are functional, and detection of latent versus active virus in infection can be 
attributed to their sequence differences.  
As our constructs are deleted for the MSD, we hypothesize that there will be an increase 
in activity in our constructs when Tat is provided during transfection, because they are not able 
to produce it on their own; whether they can produce Tat on their own in-vivo remains unknown. 
However, we would hypothesize that 
because our constructs were detectable in 
plasma virus, they were able to make Tat 
through alternative downstream splicing 
methods that our constructs do not 
contain, as we only studied the donor 
LTRs, not the full-length sequences. In 
our transfection experiments, we provide 
Tat, and therefore would expect mCherry 
expression to increase in comparison to 
Figure 3: Shuttle mCherry Vector.  
There is ampicillin resistance that allows for selection of bacteria containing 
the plasmid; we used this in our transformation reactions. mCherry 
expression is following the 5’ leader sequence and thus allows visualization 
of the activity of inserted donor construct sequences. Restriction sites are 
labeled in the plasmid and used in diagnostic digests as well as for cloning 
into the full VT1 vector.  
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when no helper is provided because high levels of transcription require Tat expression.29 
Five main steps were taken to study these donor constructs. First, stocks of all donor 
constructs were grown in bacteria (DH5a) and sequence confirmed. DH5a is an E. coli strain that 
via a bacterial transformation, allows researchers to grow up more plasmid. Then, the donor 
constructs were inserted into a shuttle containing the mCherry reporter inserted after the 5’ donor 
leader sequence in the same LTR of the deleted Gag (Fig 2, 3). After this, a segment of the 
shuttle vector containing the donor 5’ leader region was cloned into a full VT1 vector with a 
green fluorescent protein (GFP) reporter with its own constitutively expressed promoter (Fig. 4). 
If GFP is expressed in cells after 
infection, this would show a successful 
infection of the cell, while if mCherry was 
expressed this would show that the 5’ 
leader is active. This dual reporter model 
of study works by assuming that if the 
mCherry reporter is expressed, we would 
assume in vivo, the 5’ region would be 
functional and express the viral proteins. 
All constructs were inserted into the full 
VT1 vector and checked using restriction 
digests and sequencing. Then, each 
construct was transfected into 293T cells, 
whose supernatants were then harvested 
and used to infect CEM-SS cells. The data on infectivity and active versus latent infection was 
Figure 4: The full length VT1  
The VT1 vector is deleted for gag, pol, env, and nef, making it non-infectious. 
For infection and transfection experiments, VSVg for env and pCMV-HIV to 
provide the structural proteins of HIV are used to allow for viral production 
during transfection. GFP expression is off of the Spleen focusing forming 
virus promoter (SFFVp) which is constitutively expressed.  
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determined via flow cytometric analysis from the infection experiments. Flow cytometric 
analysis of transfected cells demonstrates how well plasmids transfected into the 293T cells and 
shows whether the constructs are able to express the fluorescent reporters in the presence of 
helper, a substitute for expression of the viral genes if they were there in each construct (Fig. 5). 
VT1 was our wild type control as it was the parental plasmid that we cloned all donor leader 
regions into. dGPE and mCherry were our single positive controls that showed GFP only and 
mCherry only reporters, respectively. Data was compiled and trends were observed between size 
of the genomic sequence deletion and which regions were deleted that affected their infectivity 
and latency for each construct. Three main constructs showed trends of lower transfection rates 
and infectivity coupled with an increased percentage of infected cells showing only latent 
infection, with very little proportion of infected cells containing an active infection; they were 
often only single positive for GFP but lacked high amount of double positive GFP and mCherry. 
These constructs also contained the largest deletions, with deletions in more than one stem loop. 
Constructs are numbered 1-8 and may be referred to as “Construct X” in this thesis (Fig. 1). 
However, we saw that p24 concentration in viral supernatants, a protein in the HIV capsid, as 
 
Figure 5: Example Flow Cytometric Analysis 
This figure shows an example of flow cytometric analysis used in this thesis for one of our single-color controls, dGPE, which shows GFP 
expression. (A) We first gate on cells vs debris by analyzing the side scatter (SSC) vs forward scatter (FSC). (B) We then gate on alive cells 
using DAPI expression, who’s channel for detection is often called “Pacific Blue.” Alive cells are DAPI negative. (C) We then gate on an 
open channel, to make sure we are not detecting autofluorescence. (D) Our final gate for our experiments is looking for the reporter 
expression. Therefore we create our analysis graphs for mCherry expression versus GFP expression. The channel used for detection of these 
reporters in the flow cytomeric machines are often called “PE-Texas Red” and “FITC-A” respectively. We gate on Mock cells, which should 
have no expression of either reporter, and use those same gates in order to analyze our samples and controls. Above, we see that our single 
positive dGPE control had 53.5% GFP expression during transfection. 
A    B   C   D 
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well as concentration of RNA produced in transfection, did not explain the trends that we saw in 
infectivity and latency, although some data was inconclusive and must be repeated. Finally, we 
observed that when Tat was provided in 293T transfection experiments there appeared to be no 
differences between constructs activity, as expected, showing that when Tat is provided, the 
deletion in the MSD that leads to decrease in Tat production may be recovered. However, we did 
see much lower activity in the infection experiments, which we hypothesize may be because Tat 
is no longer packaged with the virions, and thus construct’s LTRs are not as activated. Further 
investigation of full-length donor sequences may be required to determine how these constructs 
















III. MATERIALS AND METHODS 
A. Reagents 
Buffers P1, P2, P3, N3, PB, PE, QBT, QC, and QF were acquired from a QIAGEN kit; either 
for the QIAprep spin miniprep kit, QIAGEN Plasmid Midi kit, QIAquick PCR purification kit, 
or QIAquick Gel extraction kit. Buffer TE is a common molecular biological solution (10mM 
Tris•Cl , 1 mM Ethylenediaminetetraacetic acid (EDTA)) and buffer EB is an elution buffer (10 
mM Tris•Cl). Both of these reagents are also found in QIAGEN kits.  
TAE buffer is made from 40 mM Tris Base, 20 mM acetic acid, and 1mM EDTA. LB broth 
consists of 5 g/L Yeast extract, 10g/L NaCl and 10g/L Tryptone. SOC growth media is similar to 
LB broth, but contains 20g/L tryptone, 5 g/L yeast extract, 10 mM NaCl, 2.5 mM KCl, 10 mM 
MgCl2, and 20 mM glucose.  
Carbonate coating buffer contains water as the solvent, with NaHCO3 at a concentration of 
100 mM and Na2CO3 at a concentration of 37.7 mM. Blocking buffer is made by addition of 
Casein at a final concentration of 1% in PBS. The casein is heated and stirred to dissolve. The 
wash buffer contains 2 M NaCl, Tween-20 to a final volume percentage of 0.5% into PBS as the 
solvent. This is then further diluted 1:10 with water. Lysis buffer is made via addition of Casein 
to a final concentration of 0.5%. Triton-X and Tween-20 make up 0.5%, and 0.05% respectively 
of the final volume. They are added to PBS, heated, and stirred to dissolve the Casein. Dilutant 
buffer is the same as Lysis buffer, in the same ratios, except no Triton-X is added.  
B. Cell Maintenance of 293T and CEM-SS 
293 T cells are cultured in D10 media, which is made of DMEM high glucose media with 
addition of Glutamine at a final concentration of 2 mM and fetal bovine serum (FBS) so it is 
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10% of the final volume, at 37°C and 5% CO2 with a humidifying atmosphere. 293T cells are 
seeded at 105 cells for 4 days, or 2 x 105 cells for 3 days in a T25 tissue culture flask. For a T75 
flask, 5 x 105 cells for 4 days can be seeded or 106 cells for 3 days. The seeding is done by 
aspirating the old media followed by a 2 or 5 mL phosphate buffered saline (PBS) rinse 
depending on the size of the flask. Then, the cells are trypsinized, which breaks them from their 
connection to the bottom of the container, with 1 mL of 0.025% Trypsin/EDTA media. These 
cells then sit for 3 min at 37°C, followed by trypsin neutralization by 4 mL of the D10 media. 
The cells are counted via microscope and reseeded as described above.  
CEM-SS are grown in R10 media containing RPMI 1640 media, with addition of glutamine 
to a final concentration of 2mM, HEPES at a final concentration of 10mM, and 10% FBS. These 
cells are re-seeded every couple of days at a concentration of 1 x 105 cells per mL for 4 days and 
2 x 105 cells per mL for 3 days in a T25. Cells are also grown in the same cell incubator 
conditions.  
C. Sanger Sequencing 
Genscript synthetically cloned each of the 8 donor constructs into a plasmid backbone 
containing restriction sites that we could use in our later cloning steps. We confirmed these 
synthetic plasmids via Sanger sequencing. Sanger sequencing is done through the Biomedical 
Research Core Facility DNA Sequencing Core at the University of Michigan. Following their 
guidelines, we created samples containing the DNA for sequencing at a concentration of 50 
ng/µl. Buffer TE was added to make the total volume of the sample 10 µl. Primers were chosen 
that would confirm the validity of the sequence, or in later ligation experiments, the junction 
sites. Sequencing data was analyzed via the SeqMan program. Ends of the sequencing data often 
contained high background and unknown base pairs, so these were cut out from analysis. 
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Sequence data was analyzed in comparison with a reference sequence. We used this technique in 
order to confirm the junction sites in both cloning steps into the mCherry shuttle as well as the 
full length VT1 HIV vector. For confirmation of the Genscript synthesized insert sequences, we 
used the M13 reverse primer. For confirmation of the mCherry Shuttle ligation we used the 
primers HIV61-81d and mCh385r. For confirmation of VT1 correct ligation with shuttle vector 
we used the primers pUC2521 and mCh385r.  
D. Bacterial Transformation of Genscript synthetic DNA 
We received synthetically constructed DNA plasmids from the company Genscript Biotech. 
In order to create our own stock and grow up more plasmid of the constructed DNA plasmids, 
we transformed the plasmids into the E. coli competent cell DH5∝. Prior to performing this 
transformation, the Genscript plasmids were centrifuged at 6000g for 1 min at 4°C. Then, 20 µl 
of sterile nuclease free water was added to dissolve the plasmids. Finally, the samples were 
vortexed for 1 minute.  
DH5∝ was thawed on ice as it is stored at -80°C. The competent cells were then aliquoted in 
50 µl aliquots, followed by addition of the resuspended plasmid DNA. The samples were then 
placed on ice for 30 minutes. After 30 minutes, the vials were mixed and then heated at 42°C for 
20 seconds, followed by putting the samples back on ice for 2 minutes. Finally, we added 950 µl 
of prewarmed super optimal broth (SOC) growth media and then put the samples in a 37° shaker 
for 1 hour. After 1 hour, we removed the samples and plated 100 µl onto 100 µg/ml Carbenicillin 
agar plates and stored them overnight at 37°C to allow colonies to grow.  
The plasmids contain ampicillin resistance, and therefore the only colonies that survive on 
the agar plate must have taken up the plasmid. In addition, a pUC19 positive control plasmid was 
used. This cloning plasmid also contains ampicillin resistance and should transform into the 
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DH5∝ cells. Comparison with the number of colonies in the positive control shows that even if 
the sample transformations did not show colonies, the competent cells and reagents are still 
working if the positive control shows colonies. In addition, it allows calculation of the 
transformation efficiency of each test sample in comparison to the positive control. 
The next day, a colony from each plate was picked and added to 3 mL of a Luria Broth 
(LB)/Carb mix made of 3 mL of LB and 3 µl of 100 mg/ml Carbenicillin. If the cultures were for 
a miniprep, they were put into the shaker overnight at 37°C. If these cultures were for a larger 
scale midiprep, they were put into the shaker for 6-8 hours at 37°C and then diluted, taking 25 µl 
of the original culture and adding it to 25 mL of the LB/Carb mix used above. These cultures 
were shaken overnight at 37°C. The cultures were stored as glycerol stocks at -80°C containing 
or were purified via minipreps or midipreps (see below). These techniques for transformation 
were utilized to make glycerol stocks of plasmids for future use in plasmid purification or to 
supply plasmids for purification by mini or midiprep.   
In the shuttle vector transformation into DH5∝, the same steps were used, except 100 µl 
of the competent cells were used, as well as 900 µl of SOC media. After the SOC media was 
added, the shaking step was 30°C for 1.5 hours prior to plating on the Carbenicillin plates. The 
plates were stored at 30°C overnight, inverted. For the transformation of the VT1 ligated plasmid 
into competent cells, the same procedures were used as the shuttle vector transformation, except 
the competent cells Stbl2 were used. These competent cells are better for transformations of 
larger plasmids, like the full length VT1 HIV sequence, rather than DH5∝. This is because the 
full VT1 HIV construct is large, with repeating toxic elements. Thus, using a bacteria competent 
cell like Stbl2 that does not allow for as much recombination and does not expel the larger 
plasmid is required.  
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E. Glycerol Stocks 
Glycerol stocks were made from transformed bacterial cultures that were grown overnight as 
described above. Samples were put into 1.5 ml snap cap tubes. Each snap cap was centrifuged at 
6800g for 3 minutes at room temperature (RT), discarding the supernatant. Then the pellet was 
resuspended in LB broth+ 20% glycerol, transferred to a cryovial, and frozen in a dry ice/ethanol 
bath. These are stored at -80°C.  
F. Plasmid Miniprep 
Cultures that were not diluted after 6-8 hours in the shaker could undergo plasmid 
purification by QIAGEN miniprep. The samples were centrifuged at 6800g for 3 minutes at RT, 
discarding the supernatant.  
Then, the samples were resuspended in 250 µl of chilled Buffer P1 containing RNAse A and 
Lyseblue in order to resuspend the cells to decrease viscosity as well as chew up any RNA 
contamination that may be present in the samples. The lyse blue allows for visualization of when 
the cells have been lysed. Then, 250 µl of buffer P2 was added, in order to lyse the cells, 
inverting 10-12 times until the solution turned blue, letting the solution sit for 5 minutes at RT 
after. After 5 minutes, 350 µl of buffer N3 was added, inverting 10-12 times until the solution is 
colorless; this buffer neutralizes the lysis buffer. Then, the samples were run at 17,000g for 10 
minutes on a microcentrifuge. The supernatant was pipetted onto QIAprep spin column and spun 
again for 30-60 seconds. Then, 500 µl of buffer PB was added, spinning again for 30-60 seconds 
and discarding the flow through in order to bind DNA to the column. After this step, 750 µl of 
buffer PE was added and spun again for 30-60 seconds in order to wash the column, discarding 
the flow through. Finally, the column was spun for 1 min to dry, and the column was transferred 
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to a dry tube. The DNA was eluted into the new tube using 50 µl of buffer EB, letting the 
column sit for 1 minute, and then spinning at the same speed for 1 minute.  
G. Plasmid Midiprep 
Using QIAGEN plasmid midiprep kit instructions and buffers, we purified plasmid DNA in a 
larger quantity to the plasmid miniprep. First, we pelleted the competent cells at 6000g for 15 
minutes at 4°C that had been transformed with plasmid DNA (Genscript DNA, shuttle plasmid 
DNA, or VT1 vector with insert DNA) as described above. We then used 4 mL of buffer P1 
containing Lyseblue to resuspend the pellet. We then added 4 mL of buffer P2 and inverted the 
samples, making sure that the samples turned blue showing cell lysis. After letting the samples 
sit at room temperature for 5 min, we added 4 mL of chilled P3, again inverting to mix; samples 
should no longer be blue because P3 is acting to neutralize the lysis buffer. We then precipitated 
the DNA along with cells and proteins out by placing them on ice for 15 min. The samples were 
then centrifuged for 30 minutes at 20,000g at 4°C, transferring the supernatant to a fresh tube 
after spinning. The supernatant was then re-spun at 20,000g at 4°C for 15 minutes in order to 
make sure all cell particulates were removed from the supernatant in order to not clog up the 
column. The QIAGEN tip 100 was set up by running 4 mL of buffer QBT through it to 
equilibrate it. Following the spin and equilibration, the supernatant was poured onto the 
QIAGEN tip. The Qiagen spin column is made of a silica membrane that can bind DNA, as well 
as elute DNA in the presence of a low salt buffer.31 Two wash cycles of 10 mL buffer QC were 
performed on the column. The purified DNA was then eluted off the column using 5 mL of 
buffer QF and precipitated using 3.5 ml of room temperature isopropanol. The precipitated DNA 
was then centrifuged at 6000g for 1 hour at 4°C, followed by a 2 mL 70% room temperature 
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ethanol wash. The pellet was spun again at 15,000g for 10 min at room temperature. Finally, the 
pellet was airdried and dissolved in 50 µl buffer TE or 50 µl buffer EB.  
H. Restriction Digest for Diagnostic or Ligation Preparation 
We used restriction digests as a diagnostic in order to confirm plasmid or vector ligation 
steps throughout our experiments. This is because if the correct ligation is performed, we are 
able to predict the sizes of the bands after running the digests on a gel; if there are 3 restriction 
cut sites in the ligated product, we should expect to see 3 bands at their expected sizes on the gel. 
This helps to support that our ligation occurred in the correct orientation. The first restriction 
diagnostic digest we performed was to confirm that our synthetic purified plasmids received 
from Genscript didn’t contain any deletions after stocks were created by transformation of DH5∝ 
and midipreps performed (see above). The restriction enzymes AatII and HaeII were used in this 
experiment. 1 µg of each plasmid was treated with 10 units of restriction enzyme, corresponding 
to 1 µl of AatII and 1µl of HaeII, as well as 7 µl of water, and 2 µl of 10X buffer NEB CutSmart, 
for a total of 20 µl per reaction. Then, the digests were loaded into a PCR machine, set to run for 
1 hour at 37°C, then 80°C for 20 minutes; samples were then put on ice. The restriction digests 
were then loaded onto a gel to visualize (see below). This digest should create single banding 
when run on a gel for the AatII samples as only 1 AatII cut site is present in our synthetic 
plasmids, and three bands created for the HaeII as there are 3 restriction sites of HaeII.  
After growing stocks of our ligated mCherry shuttle containing the donor derived sequences, 
another diagnostic digest was performed on the purified plasmids in order to confirm that our 
ligation experiment created the restriction sites that we expect it to, supporting the hypothesis 
that the correct ends of each construct ligated into the shuttle. We treated each sample with AatII 
or BsrBI, following the same experimental procedures as above in the previous diagnostic digest. 
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AatII creates 1 band when run on a gel, while BsrBI creates 3, based on the number of cut sites 
each of these restriction enzymes contain in the insert-shuttle ligated product. We repeated this 
digest for both the mini and midprep purified plasmid DNAs.  
The final diagnostic restriction enzyme digest we performed was on the full length VT1 HIV 
dual reporter vector containing our donor derived sequences. We utilized the restriction enzymes 
AatII and BsaAI combined with SaII. These restriction digests also contained the same 
procedures as seen above in the previous diagnostic digests. However, for the double digest of 
BsaAI and SaII, 1 µl of each enzyme, corresponding to 10 units per 1 µg of DNA was added to 
each sample, and only 6 µl of water; the 2 µl of 10X NEB CutSmart buffer was kept constant 
because the amount of DNA digested was the same. We used the same experimental settings 
when running our samples on the PCR machine as seen above. There should have been 1 band 
for the AatII digest of VT1 and 4 bands for the double digest when the restriction digests were 
run on a gel. We also checked that the SbfI restriction site was present in all final VT1 constructs 
in order to confirm correct ligation following the same experimental procedures described for the 
single diagnostic digests.  
Other restriction digests on both the vector and insert were also performed prior to ligation 
experiments, to create complementary sticky ends to allow for ligation. When creating the 
mCherry shuttle vector and insert junction sites, we utilized the restriction enzymes SacI, MscI, 
and SacI combined with MscI in combination with either the vector or insert to a final 
concentration of 50 ng/µl. Single digests were utilized in order to see if the restriction enzyme 
could cut our samples; if each single digest shows the correct banding when run on a gel, we can 
assume that our double digest does in fact have the correct double cut from each enzyme. For 
construct 8, 449 V2, we substituted SacI restriction enzyme with AfIII due to different restriction 
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sites found in the donor HIV insert. Similar to the procedure above, we digested each sample of 
DNA (1µg of DNA) with 12 µl of water, 2 µl of 10X NEB CutSmart buffer, and 1 µl of the 
restriction enzyme (or 1 µl of each enzyme in the double digest mix and only 11 µl of water). We 
then combined these with 5 µl of the template DNA and ran the same PCR digest of 37°C for 1 
hour followed by 80°C for 20 minutes. These specific digests are expected to create 1 band for 
the single digest, or 2 bands for the double digest in the gel analysis (explained below).  
In order to clone the shuttle vector into the full length VT1 HIV vector we used the 
restriction enzymes AatII and SbfI single digest, as well as the double digest combination of the 
two. We followed the same ratios of water, buffer, and enzyme as described above in the shuttle 
vector cloning step. One of the two products of the double digest for both VT1 and each shuttle 
vector were ligated together in the cloning experiment (see below).  
I. Agarose Gel Preparation and Gel purification 
We created 0.8% agarose/TAE/GelRed agarose gels using 100 mL of 1X TAE buffer, 0.8 g 
of UltraPure agarose and 10 µl of 10,000X GelRed; for creation of larger gels, we doubled each 
compound in the mixture. For each gel analysis, we used 𝜆HindIII marker as our DNA ladder. 
For uncut samples, we loaded a sample containing DNA at a final concentration of 100ng/µl, 4 
µl of buffer TE and 1 µl of 10X DNA loading buffer in order to visualize the banding. For each 
restriction digest treated sample, we took the 20 µl of the sample and added 2 µl of 10X DNA 
Loading buffer. We ran each gel at 120 Volts for approximately 1 hour or more until separation 
of bands can be seen. Gels were visualized using a UV gel visualization machine.  
Gel imaging was used to analyze the diagnostic restriction digests performed to confirm 
correct synthetic sequences or ligation of DNA. In addition, gels were used to isolate specific 
fragments of DNA made by restriction digests described above based on size in a more 
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preparative manner. Many of the restriction digests mentioned above created multiple fragments 
of DNA, only one of which was of interest containing the insert, shuttle, or full-length vector 
with sticky ends, that will be cloned together. In order to isolate the correct piece of DNA, 
sequences of the shuttle, insert, or shuttle ligated to insert were used to determine the expected 
sizes of the DNA. These sizes could be compared to the bands seen on the gel in reference to the 
DNA ladder to determine the correct piece of DNA needed for cloning. This piece of DNA was 
then cut from the gel and purified following a QIAGEN QIAquick Gel extraction protocol.  
The extracted gel was first weighed. The weight, in mg, was then used to determine the 
amount of buffer QG added to the gel. Buffer QG was added to each sample in the ratio of 3 µl 
of buffer for every 1 mg of gel. The samples were then heated at 50°C for 10 minutes to melt the 
gel, vortexing every 2-3 minutes to facilitate melting. The color should have appeared yellow at 
this point, and if they did not, then 10 µl of 3M sodium acetate was added. Then, 1 gel volume of 
isopropanol was added to the sample, 1 µl for every 1 mg of gel. The samples were then applied 
to QIAquick spin column and spun for 1 minute at max speed, discarding flow through after. 
This spin cycle was repeated until the total volume of the samples was run through the column 
and flow through discarded. The column was then washed with 500 µl of Buffer QG and spun 
for 1 minute at max speed. After the spin, the flow through was discarded and 650 µl of Buffer 
PE was added to the column and let stand for 4 minutes. After the 4 minutes, the column was 
once again spun at 1 minute at 17,000g, discarding the flow through after the spin. This spin was 
repeated to dry out the column. Finally, DNA was eluted into a clean 1.5 ml tube but 100 µl of 




J. PCR Purification 
QIAGEN QIAQuick PCR purification kit and buffers were used to remove residual salts 
from the gel extraction of vectors and inserts as described above. For each sample, 5 volumes of 
buffer PB were added for every 1 volume of DNA; because we eluted with 100 µl of buffer EB 
in the gel extraction protocol, we added 500 µl of buffer PB. We then applied the samples onto 
the QIAQuick column. We then spun the samples at 17,000g for 1 min, discarding flowthrough. 
Following this, we performed a wash using 0.75 mL of buffer PE, following by a spin at the 
same speed and timing as before, discarding flowthrough. We repeated this spin again to dry out 
the column. We then eluted the purified DNA into a clean tube using 30 µl of buffer EB by 
incubating the buffer on the membrane for 1 min, followed by a spin at 17,000g for 1 minute. 
The concentration of resulting purified DNA was determined using a NanoDrop 
spectrophotometer.  
K. DNA ligation of Vector and Inserts 
Ligation of purified DNA was a vital step in the cloning process of making the full length 
VT1 plasmid vector. The two main ligation experiments performed involved ligating the 
mCherry Shuttle vector to the synthetically created donor derived 5’ sequences. The purified 
product of this ligation was then also ligated to the full VT1 vector, creating a dual reporter 
vector containing the donor derived 5’ sequences. For each of these experiments, two controls 
were utilized. The no ligase control acted as a negative control that should show that there is no 
ligation when the mediating enzyme is not present; if colonies appear on the no ligase control 
plate, the plates/samples may have been contaminated. The no insert control also acted as a 
negative control, and controls for the presence of uncut DNA (not digested correctly by the 
restriction digest) and for the presence of re-ligation of cut DNA not containing the insert.  
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The ligation samples were created by adding the vector to insert in a molar ratio of 1:3. This 
ratio favors the 1:1 vector to insert ligation, and skews away from incorrect ligations such as re-
ligation of the vector. For the ligation experiment, the vector and insert concentration added was 
1-10 ug/ml following this ratio. Four hundred units of the enzyme T4 DNA ligase were added to 
each sample except for the no ligase control. In addition, 2 µl of 10X NEB T4 DNA ligase buffer 
with ATP was added to each sample. The volume of each specific insert or vector added to each 
sample was determined using the concentration of each insert, determined by Nanodrop, as well 
as the ratio mentioned above that; based on average length of the inserts in comparison to the 
length of the vector, in the case of the mCherry shuttle vector ligation to insert 0.7 picomoles 
(pmol) of vector were added to each sample (corresponding to the 3.3 µl) as well as 0.21 pmol of 
insert. The µl of insert added thus depended on the concentration of each purified insert. Water 
was then added until each sample contained 20 µl total volume. The ligase was the last thing to 
be added to each sample. The samples were then incubated at 4°C for greater than 12 hours, 
followed by 16°C for 2 hours. The ligase enzymes in each sample were then heat inactivated for 
10 minutes at 65°C. These ligated plasmids were then transformed into competent cells, DH5a 
for the shuttle and Stbl2 for full length VT1, as described above. In the case of the VT1 ligation 
with the shuttle vector, the average shuttle length in comparison to the VT1 length corresponded 
to 0.6 pmol of insert added to each sample and 0.2 pmol of vector. The 0.2 pmol of vector 
corresponded to 4.1 µl in our experiments based off the concentration of our purified plasmid, 
and the volume of insert varied. Again, water was added so the total volume of the samples was 




L. Shuttle and VT1 vector Construction and usage  
The shuttle vector is 3696 base pairs, and is from Kathleen Collins laboratory, construct 89.6 
∆GPEN_SL4 mCherry shuttle. The VT1 vector used for cloning is from Kathleen Collins 
laboratory, construct VT1 89.6 ∆GPEN_SL4mCherry_SFG. Spleen focus forming viral promoter 
(SFFVg) is the alternate promoter site for the GFP reporter. These constructs contain deletions in 
gag, pol, env, and nef that encode important proteins of HIV. This shuttle requires helper 
(pCMV-HIV-1) and VSV-G addition during transfection and infection tests. Helper provides 
structural proteins such as gag and pol and VSV-G provides Env, all of which our construct is 
missing.  
M. Transfection in 293T cell line 
293T cells were used as the cell line for transfection of the purified VT1 dual reporter 
plasmid containing the donor derived sequences in order to produce virus particles from each 
plasmid construct.  
The first step of transfection is to seed the 293T cells the day before transfection. In a 6-
well plate, this means seeding the cells at 5 x 105 cells per well. If a larger transfection is being 
used, 2 x 106 cells can be seeded per p100 plate. On the day of the transfection, the cells are first 
visualized to see if the cells are 50-70% confluent. D10 placed in the warm water bath. Each 
construct, as well as helper (pCMV-HIV-1), pVSVG, single color control GFP (NL-dGPE-GFP) 
and r mCherry (EF1a-mCherry), and positive control VT1 parental plasmid are nano-dropped to 
determine their concentration. In the small-scale transfection using 6-well plate, per well besides 
Mock, all wells have 400 µl of 150 mM NaCl, 2 µg of pCMV-HIV helper, 1.2 µg of pVSVg, 
20.8 µl of 1 mg/ml PEI, as well as 2 µg of their plasmid DNA added. This plasmid DNA could 
be VT1, dGPE, mCherry, or one of the 8 constructs in question. For the large-scale transfections, 
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4 µg of pCMV-HIV helper, 4 µg of pVSVG, 48 µl of PEI and 4 µg of the DNA plasmid of 
interest are used, as well as addition of NaCl to 1 mL; only 1 mL is added to each p100 plate. 
The ratio of PEI used per plate is based on a ratio to the DNA amount;1 µg of DNA to 12 µL of 
PEI in the large scale transfections, where 1 µg DNA to 10.4 µl PEI is used in the small 
transfection.  
First, the DNA and helper/VSVG are added to the NaCl in a sterile polystyrene tube. These 
samples are vortexed for 2-3 seconds to mix for small scale transfections or 10 seconds for larger 
scale. Then the PEI is added and vortexed immediately for 10 seconds. The samples let sit at 
room temperature for 15 min, and then were added drop wise to the 293T cells. The cells are put 
into the cell incubator containing 5% CO2 at 37°C for 6-8 hours, until their media is replaced 
with 2 mL of fresh D10 media. In the case of the large-scale transfection, 8 mL of fresh D10 
media is replaced 6-24 hours after addition. Media replacement is so that no viral supernatant 
collected at the end of the 2 days post transfection is merely what we added to the cells; we want 
to collect the viral particles that were created due to the transfection of the 293T cells. 
At 2 days post transfection, the virus supernatant is collected. First the cells are spun out at 
300g for 6 minutes and filtered through a 0.45 µm sterile syringe filter. Aliquots of the filtered 
supernatant are saved in aliquots used for later infection, enzyme linked immunosorbent assay 
(ELISA), or real time quantitative reverse transcription polymerase chain reaction (qRT-PCR) 
experiments and stored at -80°C. The 293T cells are then harvested to analyze using flow 
cytometric analysis. First, the cells are washed with 2 mL of PBS for small scale transfections, or 
5 mL for larger scale transfections. The cells are then trypsinized with 1 mL 0.25% 
trypsin/EDTA. The cells are counted for viability and cell number under the microscope. 
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Each construct has 0.2 mL of cells transferred to a 96 well plate, including cells for 
compensation controls, which include Mock, Mock heat killed, dGPE and mCherry. Mock heat 
killed cells contain 50% mock cells that are head shocked for 1 minute at 65°C and then placed 
on ice, and 50% Mock cells. Then the cells are pelleted at 700g for 2 minutes and supernatant 
tapped off. The cells are then washed with 200 µl of fluorescent activated cell sorting buffer 
(FACS) buffer and spun again, with supernatant tapped off. All samples plus the compensation 
control Mock heat kill cells will be stained with 4′,6-diamidino-2-phenylindole (DAPI) which is 
a cell viability dye, while the solely compensation controls, Mock, mCherry, and dGPE will not 
be stained with DAPI. Thus, cells are then resuspended in 100 µl of DAPI/FACS buffer. This 
DAPI/FACS buffer consists of DAPI at a final concentration of 40 ng/mL. The compensation 
controls are resuspended with just 100 µl of FACS. Then the cells are kept on ice in the dark for 
15 minutes.  
After 15 minutes, the cells are spun at 700g for 2 minutes and supernatant discarded. The 
cells are then fixed with 100 µl of 2% paraformaldehyde/PBS and kept at RT for 30 minutes for 
fixation to occur. Finally, the cells are pelleted at 800g for 2 minutes and supernatant discarded. 
The cells are resuspended in 150 µl of FACS buffer once; the wells are rinsed again with 150 µl 
of FACs and pooled for flow cytometric analysis.  
N. Infection in CEM-SS cell line 
Similar to transfection experiments, prior to infection, cells are seeded the day before at 1:1 
with R10 media in order have cells in the log phase at the time of transduction. On the day of the 
infection, 5 x 105 cells are aliquoted into sterile snap cap tubes. These are spun in a tube holder at 
2500g for 5 minutes, and then the supernatant is aspirated. Following this, each sample is 
resuspended in 0.5 mL of the 293T viral supernatant of interest. Then, 5 µl of 400 µg/ml 
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polybrene is added in order to increase the efficiency of virus infection of the cell line. Finally, 
the samples are mixed gently and transferred to a 24 well plate. The spin infection is at 4160g at 
room temperature for 2 hours, after which the supernatant is aspirated and 0.5 mL of warm R10 
media is added back to each well. The cells are harvested 3 days later after being grown at 37°C 
in the cell incubator as described above.  
On day 3, the cells are counted for their viability. Then, 150 µl of each culture (including 
extra for compensation controls) are added to a 96 well plate. The cells are pelleted at 700g for 2 
minutes at 4°C, discarding supernatant after the spin. Then, the plate is washed with 200 µl of 
FACS buffer. The same procedure for DAPI staining described above in the transfection 
experiment is used here; once again, the compensation controls do not receive DAPI staining.   
O. PMA/ionomycin test 
Addition of PMA/ionomycin 2 days post infection of CEM-SS cells with viral supernatant is 
a technique used to show the functionality of the construct leader sequences. In our experiments, 
we stimulated CEM-SS spin infected cells (0.5 mL of volume, see protocol above) on day 2 of 
infection. We added a volume of pma/ionomycin of 1:1 with the cell volume, thus adding also 
0.5 mL. We added a 2X concentration of pma and ionomycin, which was PMA at a 
concentration of 100 ng/mL and ionomycin at a concentration of 6 µg/mL. The rest of the 
volume up to the 0.5 mL was R10 media; because we were adding this 0.5 mL of drug treatment 
to an equal volume of the cells, the final concentrations of pma/ionomycin were 1X, or 50 ng/mL 
PMA and 3 µg/mL ionomycin. The infected cells were still harvested on day 3, one day later.  
We noticed that many of the sequences did not show an increase in mCherry expression 
compared to a control lacking pma/ionomycin, yet rather they showed significant decrease in cell 
viability. Therefore, we hypothesized that the drug treatment of PMA/ionomycin at 1X 
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concentration may have been too high and caused a large enough decrease that inhibited our 
ability to see an increase in mCherry activity in the drug treated cells. Therefore, we performed a 
pma/ionomycin titration in an attempt to determine the correct concentration to treat cells that 
did not decrease cell viability.   
We followed very similar steps to the infection in CEM-SS cell line (above). However, 
instead of resuspending the cells in viral supernatant, we merely resuspended the cells in D10 
media, which is what the viral supernatant is usually found in. On day 2, we performed the 
pma/ionomycin test. We had the conditions untreated, 1X DMSO which contained 2.1% DMSO, 
and then performed serial 1:2 dilutions, taking 1 mL of each stock out and adding it to 1 mL of 
R10 media to create 1/2X DMSO, 1/4X DMSO as our control drug treatment. DMSO is usually 
toxic to cells at a concentration greater than 1%, so we could use the dilutions to compare cell 
toxicity of this drug to our pma/ionomycin test. 1X PMA/ionomycin contained 50 ng/mL PMA 
and 3 µg/mL ionomycin. We also performed 1:2 serial dilutions down to 1:4, with addition of 
R10.  
We then followed the same procedure for all samples; removal of 0.5 mL from the well was 
followed by addition of 0.5 mL of the respective solution. On day 3, these cells were harvested 
by the same protocol as noted in Infection in CEM-SS cell line (above).  
P. Enzyme-Linked Immunosorbent Assay (ELISA) 
ELISA was used to measure the p24 protein concentration in viral supernatant. P24 is a HIV 
viral capsid protein of gag, and thus its detection is possible though the use of 2 antibodies that 
detect the two different epitopes of the protein via ELISA and can show the concentration in 
ng/ml of HIV, whether it be infectious or not.  
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We used anti-p24 antibody, diluted in carbonate coating buffer at a concentration of 1 µg/ml 
by adding 5 µl of 2 mg/ml stock of anti-p24 in 10 ml of Carbonate coating buffer. The p24 
antibody we used was purified 183-H12-5c, non-biotinylated. We then put 100 µl per well in a 
NUNC Maxisorp plate and let is sit overnight in order to coat the plates with the p24 capture 
antibody. 
The next day we started the ELISA protocol. First, we washed the plate 3 times with 200 µl 
wash buffer, followed by addition of 200 µl of blocking buffer per well in order to stop 
nonspecific binding. The plates then sat at room temperature for 1 hour, no more, and were 
washed once again 3 times with wash buffer using the plate washer. Next, we prepared the 3, 10-
fold serial dilutions on the samples, as well as dGPE, mCherry and VT1. The dilutions of each 
sample are important in order to see which concentration yields an ELISA concentration that is 
accurate; if the concentration of p24 is very low, the least dilute sample may be the most accurate 
reading, and vice versa. Each sample was diluted in lysis buffer, because it contains triton that 
breaks down the HIV envelope and allows p24 to be detected. For Mock, we performed a 1:4 
lysis buffer dilution, while the other samples were a 1:10 serial dilution. In order to create a p24 
standard, we also performed 6 2X serial dilutions of a Virogen p24 standard, starting with a 
concentration of 50 ng/ml and ending with 0.78125 ng/ml. We then added 100 µl of the sample 
or standard to each well plate in triplicate and sealed for a 2-hour RT incubation or overnight 
incubation at 4°C.  
After incubation, we washed the plate 4 times in wash buffer with 1-minute incubations. 
Then, we added 100 µl of diluted anti-Gag-biotin antibody at a final concentration of 0.5 ug/ml. 
We diluted in diluent buffer. We let this detection antibody then sit for 1 hour at room 
temperature. We followed this incubation by washing the plate 4 times with wash buffer, with 1-
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minute incubations. We then added 100 µl of diluted poly-streptavidin-HRP to each plate and let 
the plate sit for 30 minutes at room temperate, which binds to the biotin antibody, and also 
contains a the horseradish peroxidase conjugation (HRP), which will allow for color 
visualization and detection when bound by its substrate tetramethylbenzidine (TMB). The final 
concentration of poly-streptavidin-HRP added to each plate was determined by a 1:10,000 
dilution, 2 µl of polySA-HRP into 10 mL of diluent buffer. We then once again washed the plate 
4 times with wash buffer, with 1-minute incubations. Then, we added 100 µl of TMB substrate 
and let incubate at room temperature until the highest concentration appear to be at saturation, 
seen via a blue color change. Then 25 µl of 0.5 M H2SO4 was added and mixed by tapping; the 
wells should turn yellow as the acid stops the HRP-TMB reaction. Finally, the color of each well 
was read at 450 nm with a reference of 650 nm on a spectrophotometer. A standard curve was 
created based on the p24 standards in order to determine the concentration of p24 in each 
sample.  
Q. Real Time Quantitative Reverse Transcription PCR (qRT-PCR) 
Real time quantitative reverse transcription PCR (qRT-PCR) was used to determine the 
amount of RNA present in viral supernatants, in order to equalize amount of viral RNA used to 
infect in CEM-SS infections. First, 750 µl of Trizol LS was added to 250 µl of viral supernatant. 
Benches were wiped down with bleach, followed by RNAse- away in order to break down any 
RNA on surfaces that could contaminate our samples. After the workspace was set up, 1 µg of 
control Raji RNA, extracted from a human cell line, was added to each sample and inverted to 
mix. The control RNA is used to calculate the efficiency of the RNA precipitation step because 
we know the amount of RNA we added. In addition, in our unknown samples, if there is not a lot 
of RNA present, RNA precipitation may not be as effective; addition of the control RNA aids in 
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ensuring there is enough RNA present to make the RNA precipitation effective. The samples 
then sat at room temperature for 1-2 minutes.  
Organic extraction of the RNA first began with addition of 200 µl of chloroform to each 
sample, shaking vigorously for 15 seconds after addition. Then, we let the samples sit for 2-15 
minutes at room temperature. We then spun the samples at 12,000g for 15 min at 4°C. We 
removed the upper aqueous layer phase to a new pre-chilled tube, being careful to not take any 
part of the interface.  
We then precipitated the RNA. First, we added 10 µg of glycoblue in order to increase 
visibility of the RNA pellet later. Then, we added 0.5 mL of isopropanol per sample and let the 
samples sit for 10 minutes at room temperature. Following this, we centrifuged the samples at 
12,000g for 15 minutes at 4°C. We then washed the RNA pellet with 1 mL of 75% ethanol and 
vortexed to mix. We centrifuged the samples once again at 7500g for 5 min at 4°C and discarded 
the supernatant. We let the pellet air dry for 5-10 minutes and then resuspended it in 10 µl of 
RNAse free water. We finished the procedure by incubating the samples for 10-15 minutes at 55-
60°C. We could stop here and store the samples at -80°C. 
Then, we moved onto the cDNA synthesis phase of qRT-PCR because we need to synthesize 
DNA from RNA in order to quantify the samples using DNA polymerase in our PCR reaction. 
First, we ran the UV treatment to destroy any DNA contaminants that may be present in the PCR 
hood. We had a no template control, a no reverse transcriptase control, and a Raji RNA control. 
We added 11 µl of water, 4 µl of 5X qScript cDNA SuperMix to a final concentration of 1X, and 
5 µl of the RNA to all samples except for the Raji direct and no reverse transcriptase controls. 
For the control RNA, we added 500 ng of the RNA, 4 µl of the SuperMix, and only 6 µl of 
water. For the no reverse transcriptase control, we added 5 µl of RNA (one sample chosen), and 
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15 µl of water. We flicked the samples to mix. We ran the cDNA synthesis reaction at 25°C for 5 
minutes, followed by 42°C for 30 min, 85°C for 5 min, and then 4°C until collection.  
Then, we performed the Gene expression Assay for beta-actin. We used the cDNA created 
from our control RNA described above to create our standards, creating 1:10 serial dilutions by 
taking 2 µl from our control Raji sample at a concentration of 50 ng/µl and adding it to 18 µl of 
nuclease free water. After thoroughly mixing, we would repeat, taking 2 µl from the new dilution 
and adding it to 18 µl of water. We used neat, 10-1, 10-2, 10-3, and 10-4 concentrations in order to 
make our standard curve. For our beta-actin reaction, we used 1 µl of 20X Taqman Beta-actin 
(ACTB) Gene Expression Assay which allows for quantification of Beta-actin in cDNA samples. 
ACTB contains the probe labelled with Fluorescein dye (FAM) that allows for quantification. 
We also added 7 µl of water, 10 µl of 2X Taqman Gene Expression Master Mix, and 2 µl of our 
template.  
For our HIV expression assay, we used the primers 9501-mRNA-F as our forward primer 
and 9629-polyA-R for our reverse primer. A final concentration of 1µM of primer, 10 µl of 1X 
Taqman Gene expression Master Mix, 7.4 µl of water, 0.25 µM concentration of our probe for 
the reaction, referred to as L9531FM, were added, and 2 µl of our template sample. FAM is also 
the fluorescent marker and the minor groove binder (MGB) is our quencher. For our standard 
curve creation for HIV we used a pVQA Standard plasmid developed by Bullen et al. which is at 
a concentration of 10 ng/µl in 10mM tris buffer.32 We got this plasmid from the National 
Institute of Health’s AIDs Reagent Program. We know that the length of the HIV standard is 
4338 base pairs, which means we can use the concentration, molar mass (660 g/mol bp), and 
Avogadro’s number of copies per mol to determine the number of copies per volume. This 
standard then allows us to determine the copies of HIV cDNA in our samples. We created serial 
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dilutions just as we did in the beta-actin assay. Specifically, we took 5 µl of the stock solution 
and added it to 5.5 µl of buffer EB to make a solution with 1 x 109 copies per 2 µl. We did 1:10 
dilutions by taking 4 µl of the starting solution and adding it to 36 µl of buffer EB. 
We ran the qPCR reaction using the optical plates with an optical film layer at 50°C for 2 
minutes, followed by 95°C for 10 minutes. Then we ran 45 cycles of 95°C for 15 seconds 
allowing for denaturation of strands, followed by 60 seconds at 60°C to allow for primer binding 
and DNA elongation. The probe fluorescence is measured during the DNA elongation stage 
when the polymerase breaks down the quencher-probe connection and allows the probe to 
fluoresce; as more cDNA is present, more probes can bind and subsequently be broken off from 
the quencher to fluoresce and be detected and quantified. Based on the known standards, the 
fluorescence of each sample can be compared to the fluorescence of the standards, specifically 
the cycle threshold value (CT), which corresponds to a specific quantity (ng) in the Beta-actin 
assay or a specific copy number in the HIV assay per volume, measured during the elongation 
stage.  
R. Flow Cytometric Analysis 
We utilized the Biomedical Research Flow Cytometry Core’s equipment at the University of 
Michigan or the Microbiology Department at the University of Michigan in order to run samples 
from transfection and infection experiments. FlowJo allows data analysis via grouping of 
samples, compensation control adjustment, and layout for display and reporting. In addition, we 
utilized Flowjo to gate first away from debris by plotting Side-scatter (SSC) vs Forward-scatter 
(FSC). Then cells were gated for live cells (those that are DAPI negative) by SSC vs DAPI 
fluorescence. Once live cells were selected, we utilized an SSC vs an open channel such as APC-
A to make sure that our final population does not contain any background due to 
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autofluorescence. Finally, we plotted our population of cells mCherry vs GFP in order to 
visualize which cells were GFP positive, mCherry positive, or both. Therefore, Flowjo analysis 
allowed us to see the percent active versus latent virus, because the active virus would be 


















IV. RESULTS AND DISCUSSION 
A. Synthetic Constructs Are Cloned Successfully into VT1 
We were unable to completely 
confirm by restriction digest and 
gel analysis that the synthetic 
sequences obtained from 
Genscript contained the correct 
synthetic construct sequences as 
bands were very streaky and 
contained more bands than 
expected (Fig 6a,b).We repeated 
the digests 4 times, and only on 
the 4th digest did streaks decrease, 
even though extra bands were still 
present (Fig 6c). We concluded 
that the extra bands may have been 
from supercoiled DNA which 
migrates faster than the linear 
DNA or from nicked DNA which 
migrates slower. Therefore, we 
moved forward with sequencing 
the plasmids in order to confirm 





























Figure 6: Diagnostic Digest of Genscript Synthetic donor constructs 
Diagnostic digest of miniprep purified plasmids of constructs 5-8. Expected band sizes for 
each diagnostic digest of Genscript synthetic plasmids (A). Diagnostic digest of construct 1-
4 was performed prior to joining the lab. Constructs show streaky bands in digests 1-3; the 
third digest attempt is shown in (B), which may be evidence of residual ethanol from 
miniprep purification of the plasmids. The final digest and gel show the clearest bands (C). 
Extra DNA fragments may show differences in coiled or relaxed states of the DNA. (B) 
Upper Comb: Lanes 1-4 AatII digest on constructs 5-8. Lanes 5-8, HaeII digest on 
constructs 5-8. Lane 9, Molecular Weight marker 𝜆HindIII digest. Lower comb: Lanes 1-4 
uncut constructs 5-8. Lane 5, Molecular Weight marker 𝜆HindIII digest. (5C) Upper comb 
Lanes 1-4 AatII digest on constructs 5-8. Lane 5, 6 empty. Lane 7, VT1 shuttle HaeII 
digest. Lanes 8-11 HaeII digest on constructs 5-8. Lane 12, Molecular Weight marker 
𝜆HindIII digest. Lower comb: Lanes 1-4 uncut constructs 5-8. Lane 5, Molecular Weight 
marker 𝜆HindIII digest.  
1  2  3  4  5  6  7  8  9 
1  2  3  4  5 
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contained our donor leader regions as well as restriction sites needed for later steps in cloning. 
As determined by sequencing, the donor constructs and restriction sites were present in our 
plasmids after DH5a transformation and miniprep spin purification.  
However, we were still able to isolate the target insert and vector sequences containing 
the correct junction sites by gel purification from our restriction digests of the mCherry shuttle 
vector and insert sequences. From sequences, we knew the expected band sizes of each insert or 
shuttle that was our target. We used UV and DNA loading dye to visualize the gel, before and 
after cutting out the target band containing our correctly digested vector and inserts. Although 
once again there appeared to be extra DNA fragments in the uncut DNA of constructs 5-8, we 
still isolated the DNA fragments that corresponded to our expected insert size (Fig 7a-d). We 
A       B          C           D 
Figure 7: Successful isolation of DNA fragments for Cloning 
(A-B) Pre-cut gels for construct 1-4 (A) and 5-8 (B). The target insert sequences are from the double digest,	with	band	length	of	around	300	
bp.	(C-D)	Post-gel	cut.	The	removed	DNA	fragments	are	no	longer	seen	on	the	gel.	These	will	be	purified	and	used	for	cloning.	
Constructs	1-4	on	left	(C)	5-8	on	right	(D).	(6A/C)	Upper	comb:		Lanes	1,	10	Molecular Weight marker 𝜆HindIII digest. Lanes 2, Shuttle 
uncut. Lane 3, SacI digest Shuttle. Lane 4, MscI digest. Lanes 6-9 Shuttle double digest SacI, MscI. Lower comb: Lanes 1, 6 Molecular Weight 
marker 𝜆HindIII digest. Lanes 1-4, double digest constructs 1-4. (6B/D) Upper comb: Lanes 1, 14 Molecular Weight marker 𝜆HindIII digest. 
Lanes 2-5, uncut constructs 5-8. Lanes 6-8, SacI digest on constructs 5-7. Lane 9, AflII digest on construct 8. Lanes 10-13, MscI digest on 
constructs 5-8. Lower comb: Lanes 1, 10 Molecular Weight marker 𝜆HindIII digest. Lane 2, Shuttle uncut. Lane 3, Shuttle AflII digest. Lane 4, 
Shuttle MscI digest. Lane 5, MscI/AflII double digest of Shuttle. Lanes 6-9, MscI/AflII double digest of constructs 5-8.  
1 2 3 4 5 6 7 8 9 10 
1 2 3 4 5 6 7 8 91011121314 
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then confirmed that these correctly sized DNA fragments did in fact correspond to our target 
vectors and inserts via sequencing, 
after ligation of the two. Expected 
insert size is around 300 bp, while 
the mCherry shuttle target DNA 
fragment should be about 3300 bp; 
we cut the gel for the bands 
corresponding to this size in order to 
purify the fragments for ligation of 
the insert and shuttle. Our restriction 
digest, gel purification, and ligation 
were successful in cloning the donor 
HIV leader constructs into the 
mCherry shuttle for 46/48 of our 
clones (Fig 8a-b); 6 transformed 
E.coli colonies were picked per 
construct in order to ensure that we 
got the correct ligation of shuttle and 
insert. We visualized the ligated 
products using a diagnostic digest 
run on an agarose gel (Fig 8a-b). Our 
ligation of insert into mCherry 





















Figure 8: Diagnostic Digest Gel Analysis to Confirm Correct Ligation  
6 colonies of E.coli per construct were chosen to purify ligated plasmid from. 
Diagnostic restriction digests are run on a gel to see if expected bands are seen 
(Fig. 3); one sample is chosen (1A, 2A, 3E, 4F, 5D, 6D, 7A, 8D, labeled in 
image) to sequence and clone into VT. (A) constructs 1-4 (B) and constructs 5-8 

















1A                      2A 
1 
3E                                 4F 





expected DNA fragments as determined by the restriction digests performed were present on the 
gel. There are 3 BsrbI cut sites and 1 for AatII; we saw the correct number of DNA fragments 
corresponding to these cut sites on our gel (Fig. 8a-b). We picked the ligated product with correct 
bands on the gel whose 
concentration was the highest to 
sequence and move forward in the 
cloning process (Fig 8a-b). We also 
performed midipreps from glycerol 
stocks of the constructs that we are 
moving forward with and confirmed 
that they showed the same DNA 
fragments as the minipreps for those 
constructs when restriction digest 
was applied; the midipreps showed 
the same banding pattern as the 
minipreps, so we can conclude that 
the midipreps can be used for VT1 
cloning  (Fig 9a-b).  
Our restriction digests for VT1 cloning also showed streaky banding patterns in all 
constructs, especially in the SbfI and double digest DNA fragments; this may be due to the SbfI 
restriction enzyme needing a longer digest than we performed because if SbfI maintains its 
attachment to the DNA it’s digesting, it can create smears on the gel (Fig 10a).33 We repeated the 













Figure 9: Midiprep purification of glycerol stocks matches minipreps 
DNA fragments created by restriction digests of miniprep plasmid purification of 
each construct show same banding patterns for midiprep purifications of that same 
replicate. This allows us to use midipreps containing higher concentrations of 
purified plasmid in later cloning steps. Constructs 1-4 (A) and 5-8 (B) Upper comb: 
Lanes 1-8, Uncut plasmids 1-4 (A) and 5-8 (B) alternating miniprep and midiprep. 
Lane 9, Molecular Weight marker 𝜆HindIII digest. Lower comb: Lanes 1-8, AatII 
digest for construct 1-4 (A) and 5-8 (B) alternating miniprep and midiprep. Lanes 
9-16, BsrbI digest for construct 1-4 (A) and 5-8 (B) alternating miniprep and 
midiprep. Lane 17, Molecular Weight marker 𝜆HindIII digest.  
Uncut      1 2 3 4 5 6 7 8 9 
1 2 3 4 5 6 7 8 9 10 11 12 13 14151617 
Uncut      1 2 3 4 5 6 7 8 9 
 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 
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The DNA fragments still showed some streaks, but isolation of the correct DNA fragments was 
still possible (Fig 10b-e).  
Ligation of the insert containing mCherry shuttle and VT1 construct was successful in 
46/48 of our selected E.coli transformed colonies, as visualized through diagnostic digest on a 
gel (11a-b). Clear separation of DNA fragments demonstrates the expected band sizes in 
reference to the expected ligated constructs restriction sites. We confirmed constructs by 
sequencing constructs 1A, 2C, 3B, 4E, 5D, 6E, 7D, 8F. In addition, we confirmed that the SbfI 
site was still present in the VT1 plasmids for sequences 1-4 (Fig. 11c). We also confirmed that 

























Figure 10: DNA fragment isolation of shuttle containing donor 5’ 
leader inserts 
(A) First restriction digest showed streaks, especially in the Sbf1 
containing digests for constructs 1-4. (B)Repeated restriction digest for 
constructs 1-4 with a 2-hour incubation time. Less streaky bands are 
seen. (C)target shuttle cut from gel for constructs 1-4. (D) constructs 5-
8 shows same streaky bands, (E) isolation of target DNA fragment is 
still viable. (9A/B/C) Constructs 1-4. (9D/E) Constructs 5-8. Upper 
comb: Lanes 1-4, uncut constucts. Lanes 5-8, AatII digest constructs 1-
4. Lanes 9-12, SbfI digest. Lane 13, 14, Molecular Weight marker 
𝜆HindIII digest. Lower comb: Lanes 1-4, double digest AatII/SbfI on 
constructs 1-4 (A/B/C) and 5-8 (D/E). Lane 5, Molecular Weight 
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the midiprep plasmid purifications for constructs 5-8 matched the minipreps for those same 







confirm that we 
have 
successfully 
cloned the 8 
synthetic 5’ 
donor leader 






and can be used 
in future investigations of the 5’ leader region’s role in latency and infectivity using the dual 
reporter vector. 



























Figure 11: Donor 5’ leader regions 
are successfully cloned into full 
length VT1 dual reporter 
Constructs 1-4 (A) and 5-8 (B) are 
successfully cloned into VT1 as 
confirmed by restriction digest of 
BsaAI and SaII, which should create 
4 DNA fragments. Only 1D and 4C 
in (A) show incorrect fragments. 
Constructs sequenced are labeled on 
the gels.   
(C)confirmation of midiprep 
consistency with minipreps for 
constructs 5-8. 6E midiprep shows 
faint banding, but concentration is 
confirmed via nanodrop; most likely 
added too little DNA in restriction 
digest steps. Bands are still 
consistent with minipreps. (D) 
Constructs 1-4 are confirmed to still 
contain the SbfI restriction site. Loss 
of this restriction site might show 
incorrect ligation of insert and 
vector. All constructs still contain 
SbfI site. (10D) Lanes 1-4, uncut 
constructs 1-4. Lanes 5-8, SbfI 
restriction digest. Lane 9, Molecular 
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B. Constructs Show that Recovery of Activity occurs when Helper containing 
Tat is provided in 293T Cells 
Transfection of 293T cells allows us to create the viral particles used to infect CEM-SS 
cells in order to study latency in packaged viral constructs. In addition, it allows us to quantify 
the expression of the dual reporters, and thus the expression of HIV genes in normal full-length 
donor sequences, in human cell lines. We utilized Mock and VT1 as controls, as well as the 




controls (Fig. 12a-c, 
14a-d); transfections 
and infections were 
performed in 2 
rounds due to the 
number of constructs 
so we had controls 
for each experiment 
(12a-c, 14a-c). 
Transfections can help establish that our leader sequences are functional at expressing the viral 
particles; expression of mCherry in transfected cells verifies the functionality of the donor leader 

















Figure 12: Controls for transfection for constructs 1-4 show between 50-70% transfection efficiency 
The controls for constructs 1-4 (Mock (A), dGPE (B), and mCherry (C)) show fairly low transfection rates. These are 
used to compare to constructs 1-4 transfection in Figure 11.  
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which can show that 
changes in sequences may 
affect transfection 
efficiency, viral gene 
expression, DNA plasmid 
quality, and even accuracy 
of concentrations used in 
transfection (Fig. 13a-h, 
15a-h). However, the 
proportion of active 
transfection remains about 
the same between constructs 
containing helper (Table 1). 
These transfections were 
performed with and without 
helper in order to ensure that 
our constructs were able to 
express the reporters and 
viable to produce virus in 
the presence of helper 
containing their missing 
structural proteins Gag, Pol, 









































Figure 13: Constructs 1-4 with and without helper show differences in rates of transfection activity  
The use of with and without helper shows that our constructs are in fact defective without the addition of the 
Gag, Pol, and Tat structural proteins. In addition, it shows that when we provide Tat, our constructs increase 
their transcriptional activity, as would be expected, and in fact show the same proportion of active 
transfection. Even though construct 1-436 PPC2 (A,B) shows a lower transfection rate than the other three 
constructs shown here, its proportion of active infection remains about the same. These transfection 
supernatants were tested for p24 concentration by ELISA. 
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Interestingly, many of the constructs, including the parental plasmid VT1 showed an increase in 
mCherry expression when co-transfected with helper. As the helper plasmid helps to encode Tat, 
we hypothesize, as expected, that use of the helper lead to an increase in transcriptional activity, 
which lead to an increase in expression of mCherry. Some of our cells showed only an mCherry 
singly positive population, which may show that overexpression of Tat lead to mCherry 
expression to a greater extent than the constitutively expressed SFFV promoter of GFP. This 
could show that 
expression of the leader 
region of VT1 may 
affect the SFFV 
promoter or GFP 
expression or, more 
likely, GFP is just dim 
in these cells, and hard 
to detect. It is unclear 
what this means for our 
constructs, and future 
investigation may be 
needed in order to 
elucidate how there is a 

























Figure 14: Controls for constructs 5-8 show higher rates of transfection 
We added the VT1 wild type (WT) parent plasmid control to our experiment in order to see the 
transfection rate without the donor 5’ leader inserts and how well expression of reporters in the parental 
strain is compared to donor constructs. We saw in this transfection that controls had a higher transfection 
efficiency than seen in the controls for constructs 1-4.  
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population without GFP expression as GFP should be constitutively expressed in transfected or 
infected cells.  
We repeated the 
transfection of 293T cells by all 
constructs. Once again, we saw 
high mCherry expression in each 
construct containing helper Tat. 
Just the mCherry vs GPE 
populations are shown in Figure 
16 and 17. As described in Table 
1, the proportion of active 
transfection in the constructs in 
comparison to the wild type (WT) 
VT1 parental plasmid when Tat is 
provided is around the same. This 
is expected because the loss of 
the MSD means transcription of 
the HIV genome, quantified by 
mCherry expression, would be 
low; but when we provide Tat, 
we should see an increase in the 
activity of our reporter to the 








































Figure 15: Providing helper during transfection leads to an increase in activity 
The proportion of active transfection in constructs 5-8 is the same; all constructs that were positive 
for GFP were also positive for mCherry in the presence of helper. This is expected because the 
MSD site deletion does not allow Tat to be spliced, unless there is an alternative splice site. When 
we provide Tat, transcription should be activated to the same extend in all constructs as differences 
in sequences are seen in stem loops important for packaging and may not affect transcription.  
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Therefore, our sequence differences were not as important in the transfection experiments 
because we provided missing elements such as Tat. The sequence differences may cause 
differences in packaging of the genome, which we can observe in the infection experiments (see 
below). It is hard to 
determine why the 
expression is only singly 
positive and not both 
mCherry and GFP 
positive, although we 
hypothesize some of the 
single mCherry positive 
cells may actually be 
double negative if the 
gating was changed or 
double positive if GFP is 
too dim for detection but 
is actually expressed. 
Overall, the ability for 
each construct to express 
mCherry implies that they 
are functional at producing viral gene products, and thus the differences in active vs latent 
populations in CEM-SS infections can be attributed to sequence differences of SL1, 2, and 3, 










Figure 16: Repeat Transfection of 293T 
Constructs 1-4  
Our VT1 parental plasmid control did not work, 
but because other controls were successful, 
there may have been human error in 
transfection of VT1. We see once again that 
proportion of active transection is around the 
same across constructs when Tat helper is 
provided.  
Figure 17: Repeat transfection of 293T 
Constructs 5-8 
These transfection sups are utilized for qRT-PCR 
analysis of viral RNA concentration They show the 
same trends seen in the first transfection of 
constructs 5-8. We see that the percentrage of 
active transfection is more or less the same across 











helper, the activity of the leader regions is higher, as would be expected. Future studies are 
needed to determine how in-vivo these constructs are able to produce Tat, as we clearly see that 
Tat is required for high transcription of these constructs. As we only studied the donor leader 
regions, later investigation of full-length sequences may be required to determine other splice 
sites needed Tat expression in these donors as the MSD is mutated or deleted.  
C. Larger SL deletions lead to lower infectivity and higher latency 
Infection of 
CEM-SS was 
performed in order 
to see the 























Figure 18: Controls for Infection of Constructs 1-4  
The infection of CEM-SS cells shows high infection rates for controls, especially dGPE. These are the controls used 
in reference to construct data in Figure 19. 
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construct and infected CEM-SS cell 
lines in order to determine how 
different donor constructs viral 
particles infect human cell lines in-
vitro. We performed infection 
experiments for all constructs, with 
and without helper (Fig. 19a-l, 21a-l), 
using the same controls as in the 
transfection experiments (Fig. 18a-c, 
20a-d). Without helper, we saw no 
infection of CEM-SS as expected, as 
our constructs lack the structural 
proteins Gag and Pol. Constructs 
with the largest deletions that 
spanned into either SL1 or SL3, 
constructs 1-436 PPC2, 5-449 
PV18VT and 7-449 V1, all showed 
the highest percentages of latency, or 
only GFP positive, in comparison 
with other constructs (Fig. 19b, 21b, 
21f). In addition, these constructs 
showed the lowest rates of infection. 








































Figure 19: Constructs 1-4 infection of CEM-SS show Construct 1-436 PPC2 has almost 
99.5% latency as well as a much lower infectivity 
(A,C,E,G) Constructs do not infect CEM-SS without helper containing Gag, Pol, and Tat 
structural proteins. (B) Construct 1-PPC2 shows 40% infection rate in comparison with almost 
95%+ in all other constructs (D, F, H) as well as a complete latent infection. 
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back to their transfection data, it appears that these three constructs did not show differences in 
proportion of active transfection when 
provided Tat. (Table 1). As expected, because 
these constructs contain deletions in more 
SLs, those regions required for packaging of 
the genome, we wouldn’t expect a lower 
transcription rate when provided Tat, but we 
would expect a lower rate of infectivity as 
seen.   
Thus, a possible conclusion is that the 
deletion of an extra stem loop yields the 






















































Figure 20: Controls for Construct 5-8 Infection 
Our single positive controls show very high rates of infection, while VT1 shows 
around 57% infection rate, and only 23% active infection.  
Figure 21: Infection for Constructs 5-8 
Constructs 5 and 7 show lower infection rate, and almost completely latent infection in 
comparison (B, F) with the other two constructs (D, H). As seen in constructs 1-4, 
infection does not occur without helper.  
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their rate of active infection. We repeated the 
first four constructs but due to timing were 
unable to perform repeats for constructs 5-8. 
In this repeat, we included a pma/ionomycin 
stimulation at day 2, which was supposed to 
show that addition of drug treatment could 
stimulate the leader regions to be more 
active. However, our constructs did not show 
an increase in activity but rather showed a 
large loss of cell viability due to drug 
stimulation, which resulted in lower 
percentages of infectivity (Fig 23a-h). In the 
future, we would hope to repeat the infection 
experiments for constructs 5-8 as well as 1-4 
again, using a lower concentration of 
pma/ionomycin mentioned below, in order to 
support our initial transfection evidence that our leader sequences are functional and can be 
stimulated, and when they show latent infection they are in fact latent rather than just 
dysfunctional. This would help support our conclusions that when 2 stem loops are deleted in our 




















Figure 22: Repeat 1-4 constructs infection Controls 
Both our mCherry control and VT1 control did not show high infectivity (D, E), 




infection data of 
interest is in Table 1, 
showing that construct 
1, 5, and 7, those that 
contain the largest 
deletions, also have the 
lowest rates of 
infection and highest 
rates of latency. 
Unfortunately, we did 
not use a WT VT1 
control in our first 
transfection and 
infection experiments 
for constructs 1-4, and 
for our repeat of these 
constructs, our VT1 
control was not viable. 
Therefore, it is difficult 








































Figure 23: Repeat of construct 1-4 Infection with PMA/ionomycin stimulation 
PMA/ionomycin stimulation lead to a loss of viability in cells, leading to a decrease in infectivity. 
Therefore, we could not quantify whether our leader sequences could be stimulated by drug treatment at 
this concentration. Similar trends to the previous construct 1-4 infection show 1-PPC2 infects at the 
lowest rate with the highest percentage of latent infection in the pma absent infection.  
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infection data for constructs 1-4 to see if their infection rate is in fact lower than WT.  
However, we suggest that the trends we see for constructs 1-4 may still demonstrate that 
when there is a deletion that is only in one stem loop, the rate of infection is higher in 
comparison to when the deletion spans across more than one stem loop. As seen in Table 1 for 
constructs 1-4, constructs 2 and 4 have the highest active infection. These constructs only contain 
point mutations in the MSD, and thus, as we would expect, would have higher activity in 
comparison to construct 3 that has a deletion spanning across SL2, and even higher than 
construct 1 that has a deletion that spans from SL2 into SL1. We even hypothesize that the point 
mutation constructs may be able to produce some Tat expression on their own that could drive 
their higher activity and that the deletion of more than one stem loop affects the ability to 
package the HIV genome and thus decreases infectivity.  
In constructs 5-8 we saw that in comparison to WT VT1, infection rate was lower for 
constructs 5 and 7 and higher for constructs 6 and 8. Constructs 5 and 7 contain a deletion that 
spans from SL2’s MSD into SL3, whereas constructs 6 and 8 contain a deletion only in SL2. 
Therefore, we hypothesize that a deletion that spans into more than one stem loop, regions that 
are important for packaging, decreases the infectivity rate lower than WT, whereas if just the 
MSD is deleted, packaging of the virion may still be viable, as infectivity higher than WT is 
seen. In general, across all constructs, we see that when total infection rate is lower, the 
proportion of active infection also decreases. This has been shown in previous investigations by 
our lab, and thus helps support those conclusions that lower infectivity can lead to higher 
latency. More experiments are required to see if the rates of active infection, when infection rate 











Construct Trial 1 2 1 2 
1-436 PPC2 45.5 26.0 87.8 1 
2-436 PV106BVT 67.5 57.0 81.2 1 
3-449 PPC 69.2 33.0 89.9 1 
4-449 CL2 70.6 40.0 86.9 1 
WT VT1  0*  0* 
5-449 PV18BVT 37.0 15.0 100 98.3 
6-449 PV24BVT 47.0 7.4 100 87.9 
7-449 V1 24.0 17.4 100 99.4 
8-449 V2 42.0 15.1 100 96.0 
WT VT1 37 24.7 94.6 85.6 
Summary Infection 






Construct Trial 1 2 1 2 
1-436 PPC2 40.4 15.2 0.52 0.74 
2-436 PV106BVT 95.7 72.5 17.35 5.43 
3-449 PPC 95.2 36.0 11.87 1.48 
4-449 CL2 97.9 54.2 24.41 6.09 
WT VT1  0*  0* 
5-449 PV18BVT 38.3   1.59   
6-449 PV24BVT 85.1   5.96   
7-449 V1 30.6   0.79   
8-449 V2 62.8   2.36   






Table 1: Summary of Important 
Transfection and Infection Data is 
shown 
Constructs 1, 5, and 7 show trends of 
lower transfection rate, lower infection 
rate and lower active infection in trials 1 
and 2. For transfection data, we see that 
the proportion of active transfection 
when helper is provided is more or less 
the same across constructs, as expected, 
even if the total rate of transfection 
differs; the differences in LTR sequences 
for constructs are in sites important for 
packaging (SL1 and SL3) not 
transcription, so if we provide Tat 
needed for transcriptional activation, we 
should see activation in all constructs. 
For infection experiments, Tat may not 
be packaged within the virions because 
of the deletion of the MSD site, so we 
see differences between activity in 
constructs. In addition, the differences in 
deletion size between constructs can help 
explain the differences in infectivity that 
we see. The three constructs with the 
lowest active infection are constructs 1, 5 
and 7. Construct 1 contains a large 
deletion spanning into Stem loop 1, and 
constructs 5 and 7 have deletions 
spanning into stem loop 3; these 
deletions are larger than the other 
constructs which only have deletions or 
mutations in stem loop 2. The most 
active constructs appear to be constructs 
2 and 4, which only contain a point 
mutation in the MSD, and thus may even 
be able to express some Tat from the 
MSD on their own. 
Unfortunately, VT1 controls were not 
viable in our construct 1-4 experiments, 
and thus we are unable to ensure that our 
rate of infectivity and active infection 
was the same as WT, and in fact did 
differ between constructs. In our 
infection for constructs 5-8, we see that 
deletions in more than one stem loop, 
SL2 to SL3 which are present in 
constructs 5 and 7, lead to a lower 
infection rate and lower activity rate. 
Although the other constructs 6 and 8 did 
not show as much activity as WT, it 
appears that they still shower a higher 
activity than 5 and 7, as would be 
expected because 6 and 8 only contain a 
deletion in SL2, not spanning into more 
than one SL.  
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D. qRT-PCR and ELISA Demonstrate Different RNA Packaging and Release 
into Medium and Protein Production  
A possible explanation for the difference in infection rates could 
be that the less infectious constructs had produced less viral 
particles during transfection, thus 
when infecting with the same 
volume of supernatant across 
constructs, the less prolific would 
not infect as well. In order to test 
this, we took the viral supernatants 
from the transfection experiments 
shown in Figure 13 and 15 and 
performed ELISA in order to 
determine the concentration 
of p24 present in the 
supernatant (Table 2). We 
determined that there 
appeared to be no 
differences in the amount  
of p24, a protein that makes 
up the capsid protein of 
HIV, within each 




Mock 1 0 
dGPE 1 433,877 





Mock 2 0 
dGPE 2 557,976 



















Figure 24: Raw Data for Beta-Actin Assay of Viral Supernatants 
The standard curve (A) made from Raji Control RNA shows where samples fall onto the 
standard curve line. The amplification plot data demonstrates varying levels of RNA 
concentration.  
Table 2: ELISA data shows no 
significant explanation for lower 
infectivity rates of constructs  
ELISA data for all 8 constructs, 
including each control for infection 
experiments 1-4 and for 5-8 are 
shown to the left. Control “1” denotes 
for constructs 1-4 and “2” denotes 
constructs 5-8. 10-fold serial dilutions 
were performed in order to ensure that 
accurate measurements for protein 
concentration were determined. Some 
of the higher concentration dilutions 
were omitted from average 
calculations. These may have reached 
saturation prior to collection, meaning 
our concentration estimate would be 
undervalued. We noticed that the 
concentration of viral proteins in the 
viral supernatants was across the 
board similar between constructs, and 




thus a lack of virion particles used in infection cannot explain the difference in rates of infection; 
the constructs contained more or less equal amounts of p24 in the viral supernatants. These same 
viral supernatants were used in the infection experiments shown in Figures 19 and 21, thus our 
differences in infectivity cannot be attributed to differences in number of viral particles in the 
supernatant.   
We then wondered whether the 
differences in infection could be based on 
a difference in amount of HIV RNA 
packaged into virions. In order to test 
this, we took the transfection 
supernatants from transfections in Figure 
16 and a transfection experiment repeat 
of constructs 5-8 (data not shown) and 
extracted RNA from each sample. We 
then synthesized cDNA from the RNA 
extracts and performed qRT-PCR in 
order to quantify the genomic 
concentrations of each transfection (Fig. 
24a-b, Fig 25a-b, Table 3). Our goals were to use the genomic concentration data in order to 
infect CEM-SS cells with an equal concentration of HIV RNA rather than an equal volume of 
viral supernatant as we had in previous infection experiments. However, due to timing, we were 
unable to complete this final CEM-SS infection and hope to determine the role of RNA 














Figure 25: HIV qRT-PCR results of Viral Supernatants 
The standard curve made of HIV standard (A) shows a high R2 value as seen 
in the Beta-actin assay, as well as where samples fall onto the curve. The 
amplification plot shows varying data; the most right amplification curves are 
Mock cells, and would be expected to have no HIV detectable.  
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viral supernatants are not the same tested for ELISA, however, we hope that the trends observed 
in concentration of RNA would hold across all transfection supernatants.  
We performed both a Beta-Actin Assay in our viral supernatants as a control in order to 
determine our RNA extraction efficiency’s (Fig. 24a-b) as well as the experimental HIV targeted 
assay (Fig 25a-b). We calculated the quantity of RNA in each PCR reaction using the standard 
curves for Beta actin (Fig. 24a) and for HIV (Fig. 25a), and then used information on the 
dilutions we used, often a 1:10 dilution, and RNA extraction efficiency calculated using our 
control RNA in order to calculate the quantity of RNA in our viral supernatants; Results are 
shown in Table 3. The Beta actin assay demonstrated very poor RNA extraction, with the best 
RNA extraction of VT1 at 40% efficiency (Table 3). It is interesting that the RNA extraction for 
all constructs was so low and begs the question of whether data for HIV RNA quantity is 
accurate due to such a low extraction rate. Although our efficiency of extractions was so low that 
there may have been large variability, we still used the efficiency numbers to calculate HIV RNA 
copy number in the viral supernatants.  
From our qRT-PCR experiment, it appears like there are no significant trends that show 
that our constructs that showed the lowest rate of infection and lowest proportion of active 
infection, constructs 1-436 PPC2, 5-449 PV18VT, and 7-449 V1, produced viral supernatant 
with a lower copy number of RNA genome, in either the raw data or data corrected for percent 
efficiency of RNA extraction. Although 1-436 PPC2 did contain a lower copy number than other 
constructs in its experimental cohort, constructs 5 and 7 did not show this trend. Repeating the 
RNA extraction and qRT-PCR may be necessary in order to determine trends in viral copy 
number in transfection supernatants, as well as using those number for infection of CEM-SS 
cells. Cycle threshold (CT) values in comparison with CT values of the standards are used to 
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calculate the concentration of cDNA in the PCR reactions. If we performed a 1:10 dilution on 
these samples, we then multiplied this concentration by 10 to get the concentration (or copy 
number) of the undiluted sample; these are shown in the left column of the Beta actin and HIV 
mRNA assay of Table 3.  
Although the RNA extraction was very inefficient, we also calculated the copy number 
for HIV mRNA using the percent efficiency of extraction determined by the Beta-Actin Assay. 
We took our copy number and divided it by the percent efficiency to get the expected total copy 
number per volume in our viral supernatants; this is shown in the right column of HIV mRNA 
Assay in Table 3. All values were in the dynamic range of the standard curve (1 x 107 cop/µl to 
10 cop/µl), because we performed the 1:10 dilutions. The qRT-PCR data is suggestive that our 
conclusions that constructs with smaller deletions have a lower degree of latency is valid and is 
not because of a difference in HIV genome packaged. However, our data remains somewhat 










Beta-Actin Assay Average concentration of Beta-
Actin (ng/µl) 
Percent efficiency RNA extraction, 
(50 ng/µl expected) 
Mock 0.61 1.22 
dGPE 4.18 8.36 
mCherry 2.99 5.98 
VT1 2.49 4.98 
1-436 PPC2 1.3 2.6 
2-436 PV106BVT 0.52 1.04 
3-449 PPC 12.57 25.14 
4-449 CL2 0.01 0.02 
  
Mock 4.65 9.3 
dGPE 4.44 8.88 
mCherry 18.16 36.32 
VT1 20.29 40.58 
5-449 PV18VT 0.03 0.06 
6-449 PV24VT 0.85 1.7 
7-449 V1 0.8 1.6 
8-449 V2 0.67 1.34 
HIV Assay Average copy number HIV 
mRNA (cop/µl)  
Copy number taking into account 
Percent efficiency (cop/µl) 
Mock 0 0 
dGPE 12,985,627 155,330,466.50 
mCherry 110 1,839.50 
VT1 3,545,050 71,185,743 
1-436 PPC1 215,180 82,761,53.8 
2-436 PV106BVT 2,784,869 267,775,865.40 
3-449 PPC 4,616,749 18,364,156.70 
4-449 CL2 4,684,601 23,423,005,000  
Mock 0 0 
dGPE 12,589,772 141,776,711.70 
mCherry 4,348 11,971.40 
VT1 15,581,428 38,396,816.20 
5-449 PV18VT 17,352,727 28,921,211,667 
6-449 PV24VT 491,804 28,929,647.10 
7-449 V1 5,379,100 336,193,750 
8-449 V2 1,829,612 136,538,209 
 
 
Table 3: qRT-PCR results for transfection supernatants 
There appear to be no significant trends in copy number per volume between constructs that can be releated back to their sequence 
differences or active infection rates. The RNA extractions across the board were very ineffective, so cop/ul was calculated from raw data 
and from using the RNA extraction efficiency. In both ways of calculating copy number, no trends can be seen that would explain the trends 
seen in lower infectivity of constructs 1, 5, and 7.  
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E. PMA/ionomycin Tests Provide Future Directions of Study 
We have demonstrated that our 
current pma/ionomycin concentration used 
for stimulation of infected CEM-SS cells by 
constructs 1-4 lead to a large decrease in cell 
viability and no extra mCherry expression 
(Fig. 23). We sought to determine what 
concentration of drug treatment would 
maintain cell viability and thus allow us to 
show that our donor leader regions could be 
stimulated to produce mCherry by 
pma/ionomycin in order to show 
functionality. We performed CEM-SS 
infection by Mock cells, followed by 
pma/ionomycin stimulation two days post 
infection using different concentrations of 
pma/ionomycin (discussed in detail in 
materials and methods). We used DMSO, 
another solvent known to have cell toxicity 
at a concentration greater than 1%, as a 
control (Fig 26a-d), although we saw that 

































Figure 26: DMSO treatment of Mock cells act as controls for cell viability 
DMSO treatment of Mock cells allows us to quantify cell viability, as DMSO is 
known to be toxic about 1% concentration, which corresponds to about 1/2X DMSO 
treatment as occurring to our protocols. However, almost all concentrations of DMSO 
appeared to not be very toxic to our Mock cells. 1/2X DMSO treatment repeat 2 




1.05% concentration. We saw that 
cell viability increased as 
concentration of pma/ionomycin 
decreased, as expected (Fig. 27a-c, 
Table 4). We also repeated the 
pma/ionomycin titration to confirm 
our results; Only the first two gates are shown that show cells and DAPI staining for dead vs 
alive cells for the repeat experiments in Figure 29a-c. From our data, it appears that using a 
concentration at 1/2 what we used before in our infection experiments increases cell viability to 
about 90% (see Materials and Methods for details on concentrations). We propose using a 1/2X 
PMA/ionomycin treatment, corresponding to 25 ng/mL PMA and 1.5 µg/mL ionomycin in future 
infection and drug stimulation experiments to determine functionality of our leader regions. 
































 Figure 28: DMSO treatment for repeat pma/ionomycin titration 
We see similar trends of high cell viability even with the control 
drug treatment.  
Figure 27: PMA/ionomycin titration shows cell viability increases with lower 
drug concentration 
We determined cell viability using DAPI vs SSC gating shown in the second 
column. There also appears to be an outlier in the 1/4X PMA/ionomycin treatment 
(C*). These plots show the representative gating we used for the pma/ionomycin 





























1 98 99 99 98 88 87 21 
2 98 99 47 96 87 93 93 
Avg 98 99 99 97 87.5 90 93 
Standard 
Deviation 
0 0 36.8 1.4 0.7 4.2 50.9 















1 97 97 97 94 84 90 91 
2 88 97 97 93 76 87 87 
Avg 92.5 97 97 93.5 80 88.5 89 
Standard 
Deviation 
6.4 0 0 0.7 5.7 2.1 2.8 























Figure 29: Repeat 
titration of 
PMA/ionomycin shows 
similar cell viabilities 
Titration of 
PMA/ionomycin shows 
that 1/2X has about 95% 
cell viability and may be 
viable for experimental 
infections.  
Table 4: Summary of PMA/ionomycin drug titrations 
Use of 1/2X PMS/ionomycin concentration increased the cell 
viability, especially in the second trial. The numbers highlighted in 
yellow appear to be outliers, so they were not used in calculation of 
the averages, although they were used in standard deviation 
calculations. Future CEM-SS stimulation experiments should utilize 
1% PMA and 0.5% ionomycin treatments. Refer to Materials and 
Methods for more information on concentration of drug treatments.  
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F. Final Conclusions 
In conclusion, we have determined that substitution of donor LTR sequences with 
deletions in more than one stem loop were functional in expression of both mCherry and GFP 
reporters in transfection. We showed that our constructs, when Tat is provided, a protein that we 
would expect our constructs unable to make due to the MSD deletion or mutation, were able to 
increase activity; the constructs showed around equal proportion of active transfection. 
Therefore, the sequence differences in the packaging regions of the LTR appear to not affect 
rates of active transfection, only the fact that the MSD is deleted, and Tat is provided to activate 
transcription.  
Therefore, our transfection data suggests that Tat is required for these constructs to have 
high activity, and when we do not provide Tat, our constructs cannot produce it off of the MSD. 
However, because we see these constructs expressed in-vivo, we propose that there may be a 
downstream splice site that allows for Tat expression. Future investigation of the role of Tat in 
MSD deleted or mutated constructs could involve adding a lentivirus that expressed Tat and a 
different color reporter during infection experiments. We would expect that if we provide Tat 
during infection to our constructs, the activity should increase as seen in transfection. Similarly, 
we could make full-length reporter constructs to see if the activity during infection increases in 
comparison to our current constructs, as would occur if there were a downstream splice site for 
Tat. Our constructs would not have included this possible downstream site, as they only 
contained the LTRs inserted into our dual reporter VT1.  
For our infection experiments, we saw that when there was only a point mutation in the 
MSD, there was a higher degree of activity. In comparison, constructs with the lowest activity 
had deletions that spanned into more than one stem loop, and thus may have been unable to 
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package the genome correctly. We suggest that these differences in infectivity cannot be 
contributed to differences in virion particles or genomic concentration in the viral supernatants 
used to infect the human cell line, although these experiments need to be repeated to confirm this 
conclusion. We propose that there is a correlation between infectivity and latency in HIV-1, as 
suggested by other lab members work, where lower rates of infection are correlated with higher 
rates of latency. For future study, we are interested in determining what causes the correlation 
between infectivity and latency, as it is clear that an extra deletion in SL1 (construct 1) vs SL3 
(constructs 5 and 7) does not affect the outcome, only the fact that there is a deletion in another 
SL besides the MSD in SL2.  
This could be of interest in studying because the cure for HIV relies on diminishing the 
latent integrated population that is maintained in hosts on antiretroviral therapy; if future 
research could determine why the constructs with deletions in more than one stem loop are able 
to maintain their low infectivity rate, it could help elucidate mechanisms to how the latent 
population is maintained, and possibly how to eradicate it. A possible hypothesis for future study 
is that because the stem loops are required for assembly and packaging of the gRNA, when these 
are deleted or mutated, the virus is required to use alternative methods for packaging and 
assembly that yield the virus less infectious. We propose a future infection experiment that 
equalizes out the rate of infection, hopefully be infecting with equal numbers of HIV genome, in 
order to see how the rates of active infection compare across constructs and between constructs 
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